Table 1

Candidate SNPs, Their Frequencies, and Their Associations With On-Treatment Reactivity at 12 to 24 h, 30 Days, and 6 Months After PCI

SNPAlleleAllelic FrequencyOn-Treatment Reactivity
After PCIAt 30 DaysAt 6 Months
R2p ValueR2p ValueR2p Value
rs4244285CYP2C19*20.150.0652.2 × 10−150.1041.3 × 10−170.0711.9 × 10−11
rs7254579CYP2B6*1B0.320.0130.00170.0020.560.0060.12
rs4803418CYP2B6*1C0.300.0070.020.0010.740.0030.37
rs4803419CYP2B6*1C0.300.0060.040.0020.580.0020.51
rs12248560CYP2C19*170.230.0050.080.0220.00040.0150.01
rs11264579PEAR10.200.0030.210.0040.240.0090.06
rs5918ITGB30.150.0030.210.0130.010.0080.07
rs12410842VAV3/NTNG10.070.0030.230.0020.540.0050.17
rs2769668VAV30.070.0030.230.0020.540.0050.17
rs17786144ITPR10.130.0030.240.0020.44<0.0010.90
rs8192719CYP2B6*90.240.0020.300.0050.180.0030.34
rs3745274CYP2B6*60.230.0020.330.0050.190.0030.33
rs1045642ABCB1 3435C→T0.470.0020.320.0010.970.0020.49
rs41299597PEAR10.030.0020.340.0020.440.0090.05
rs822442PEAR10.110.0020.390.0010.73<0.0010.92
rs5746223RAF10.100.0020.420.0010.990.0010.81
rs662PON1 Q192R0.310.0020.420.0010.610.0010.69
rs41273215PEAR10.100.0020.450.0010.75<0.0010.99
rs350916MAP2K20.460.0020.450.0010.92<0.0010.85
rs17228705PDGFC0.160.0010.510.0010.77<0.0010.93
rs3737224PEAR10.100.0010.530.0010.69<0.0011.00
rs6450105ITGA1/ITGA20.270.0010.270.0010.44<0.0010.88
rs6785930P2RY120.300.0010.580.0070.080.0070.08
rs41291556CYP2C19*80.0020.0010.320.0030.140.0050.07
rs1128503ABCB1 1236C→T0.440.0010.610.0040.290.0030.36
rs41305896ITGA2/ITGA10.0250.0010.390.0010.41<0.0010.94
rs168753F2R (PAR-1)0.160.0010.710.0030.320.0010.71
rs16846673P2RY120.0020.0010.450.0010.80<0.0010.89
rs2290159RAF10.20<0.0010.940.0020.560.0020.58
rs3729931RAF10.35<0.0010.960.0020.530.0010.83
rs776746CYP3A5*30.07<0.0010.900.0010.830.0030.38
rs17041401ITPR10.41<0.0010.920.0060.130.0020.57
rs28365083CYP3A5*2A0.01<0.0010.500.0010.870.0030.16
rs28399504CYP2C19*40.002<0.0010.910.0020.290.0010.53
rs4986893CYP2C19*30.008<0.0010.77NANANANA
rs851007MAPK140.48<0.0010.990.0010.710.0010.74
rs956115IRS-10.08<0.0010.980.0070.07<0.0010.92
rs72552267CYP2C19*60§<0.0010.910.0010.410.0010.47
rs56337013CYP2C19*50NANANANANANA
rs72558186CYP2C19*70NANANANANANA
rs45593941CYP3A5*3F0NANANANANANA

NA = not available because no carriers of the given allele were identified; PCI = percutaneous coronary intervention; SNP = single nucleotide polymorphism.

  • R2 values are adjusted for clinical covariates and at 30 days and 6 months for treatment assignment.

  • Allelic frequencies were obtained from the cohort of 611 patients in whom genetic samples were obtained at the time of platelet function assessment after PCI and before study drug assignment or study exit to avoid bias due to the study design. See Methods for more details.

  • A cutoff of p < 0.0012 was determined a priori as the level at which to determine statistical significance to correct for multiple comparisons.

  • § No carriers were present in the population enrolled at screening 12 to 24 h after PCI.